- Home
- TMQ vs NYXH Comparison
TMQ vs NYXH Comparison
Compare TMQ & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- NYXH
- Stock Information
- Founded
- TMQ 2004
- NYXH 2009
- Country
- TMQ Canada
- NYXH Belgium
- Employees
- TMQ N/A
- NYXH N/A
- Industry
- TMQ Precious Metals
- NYXH Medical/Dental Instruments
- Sector
- TMQ Basic Materials
- NYXH Health Care
- Exchange
- TMQ Nasdaq
- NYXH Nasdaq
- Market Cap
- TMQ 249.6M
- NYXH 250.5M
- IPO Year
- TMQ N/A
- NYXH 2021
- Fundamental
- Price
- TMQ $1.55
- NYXH $6.80
- Analyst Decision
- TMQ
- NYXH Strong Buy
- Analyst Count
- TMQ 0
- NYXH 3
- Target Price
- TMQ N/A
- NYXH $15.00
- AVG Volume (30 Days)
- TMQ 398.2K
- NYXH 128.4K
- Earning Date
- TMQ 10-07-2025
- NYXH 08-18-2025
- Dividend Yield
- TMQ N/A
- NYXH N/A
- EPS Growth
- TMQ N/A
- NYXH N/A
- EPS
- TMQ N/A
- NYXH N/A
- Revenue
- TMQ N/A
- NYXH $4,716,818.00
- Revenue This Year
- TMQ N/A
- NYXH $209.22
- Revenue Next Year
- TMQ N/A
- NYXH $219.37
- P/E Ratio
- TMQ N/A
- NYXH N/A
- Revenue Growth
- TMQ N/A
- NYXH N/A
- 52 Week Low
- TMQ $0.47
- NYXH $5.55
- 52 Week High
- TMQ $2.09
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- TMQ 43.16
- NYXH 41.07
- Support Level
- TMQ $1.43
- NYXH $6.01
- Resistance Level
- TMQ $1.64
- NYXH $8.59
- Average True Range (ATR)
- TMQ 0.10
- NYXH 0.55
- MACD
- TMQ -0.03
- NYXH -0.10
- Stochastic Oscillator
- TMQ 22.55
- NYXH 30.64
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.